Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.17 is 380% above its 3-year average of 0.04, near the high end of its 3-year range (-0.17–0.17).
As of the fiscal period ended Tuesday, June 30, 2026. 17.51% above its 12-month average of 0.15.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.17.
DEBT TO EQUITY RATIO
0.17
DEBT TO EQUITY RATIO AVG TTM
0.15
DEBT TO EQUITY RATIO AVG 3Y
0.04
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+17.51%
CURRENT VS 3Y AVG
+345.89%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.14
median of 467 covered companies
CURRENT VS SECTOR MEDIAN
+21.96%
vs the sector median at left
Market Cap
$940.12M
Debt to Equity Ratio
0.50
TTM Avg
0.08
3Y Avg
0.06
5Y Avg
0.04
Market Cap
$917.68M
Debt to Equity Ratio
0.04
TTM Avg
0.05
3Y Avg
0.06
5Y Avg
0.07
Market Cap
$986.21M
Debt to Equity Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$988.93M
Debt to Equity Ratio
0.02
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$892.87M
Debt to Equity Ratio
0.01
TTM Avg
0.06
3Y Avg
0.07
5Y Avg
0.10
Market Cap
$892.20M
Debt to Equity Ratio
0.00
TTM Avg
0.03
3Y Avg
0.03
5Y Avg
0.03
Market Cap
$1.01B
Debt to Equity Ratio
0.02
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.01
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CeriBell, Inc. (CBLL) | $949.71M | 0.17 | 0.15 | 0.04 | N/A |
| Kura Oncology, Inc. (KURA)vs › | $940.12M | 0.50 | 0.08 | 0.06 | 0.04 |
| HealthStream, Inc. (HSTM)vs › | $917.68M | 0.04 | 0.05 | 0.06 | 0.07 |
| Bioventus Inc. (BVS)vs › | $916.63M | 1.16 | 1.98 | 1.88 | 1.60 |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $986.21M | N/A | N/A | N/A | N/A |
| Aktis Oncology, Inc. (AKTS)vs › | $988.93M | 0.02 | N/A | N/A | N/A |
| Arbutus Biopharma Corp (ABUS)vs › | $892.87M | 0.01 | 0.06 | 0.07 | 0.10 |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $892.20M | 0.00 | 0.03 | 0.03 | 0.03 |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $1.01B | 0.02 | 0.01 | 0.01 | 0.01 |
| Janux Therapeutics, Inc. (JANX)vs › | $1.01B | 0.02 | 0.02 | 0.05 | 0.03 |
Debt/Equity
0.17
Current Ratio
9.18
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.17 |
| 2026-03-31 | 0.16 |
| 2025-12-31 | 0.14 |
| 2025-09-30 | 0.13 |
| 2025-06-30 | 0.13 |
| 2025-03-31 | 0.12 |
| 2024-12-31 | 0.11 |
| 2024-09-30 | -0.16 |
| 2024-06-30 | -0.17 |
| 2024-03-31 | 0.00 |
| 2023-12-31 | -0.13 |
| 2023-09-30 | 0.00 |
| 2023-06-30 | 0.00 |
| 2023-03-31 | 0.00 |
